Publications by authors named "J J Delord"
Article Synopsis
- * It introduces modern analysis techniques that factor in the timing and recurrence of immune-related AEs (irAEs) in cancer patients treated with immune checkpoint inhibitors, based on the MOTIVATE prospective study findings.
- * Results showed variations in the prevalence and timing of irAEs between melanoma and non-small cell lung cancer (NSCLC) patients, leading to more comprehensive safety assessments that can guide clinical and regulatory decisions.
Introduction: Advanced cutaneous melanoma is a skin cancer characterized by a poor prognosis and high metastatic potential. During metastatic spread, melanoma cells often undergo dedifferentiation toward an invasive phenotype, resulting in reduced expression of microphthalmia-associated transcription factor (MITF)-dependent melanoma antigens and facilitating immune escape. Tumor Necrosis Factor (TNF) is known to be a key factor in melanoma dedifferentiation.
View Article and Find Full Text PDFRandomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden.
J Immunother Cancer
August 2024
Article Synopsis
- Checkpoint inhibitor therapy, particularly nivolumab combined with ipilimumab, shows promise for patients with high tumor mutational burden (TMB-H) across various tumor types, indicating a potential survival benefit.
- The study involved 201 patients with advanced solid tumors who were resistant to standard treatments; they were randomly assigned to receive either the combination of nivolumab and ipilimumab or nivolumab alone, with the effectiveness measured based on objective response rates.
- Results demonstrated higher response rates in patients with TMB-H tumors who received the combination therapy, and the safety profile was acceptable, suggesting this treatment could be beneficial for patients with limited options.
Background & Aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC).
Methods: Eligible patients who had progressed or were intolerant to sorafenib received escalating doses of capmatinib 200 mg, 300 mg, and 400 mg twice a day (bid) plus spartalizumab 300 mg every 3 weeks (q3w) in the phase Ib study. Once the recommended phase II dose (RP2D) was determined, the phase II study commenced with randomised 1:1 treatment with either capmatinib + spartalizumab (n = 32) or spartalizumab alone (n = 30).
Background: Despite multimodal therapy, 5-year overall survival for locally advanced head and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of pembrolizumab to concurrent chemoradiotherapy for locally advanced HNSCC.
Methods: In the randomised, double-blind, phase 3 KEYNOTE-412 trial, participants with newly diagnosed, high-risk, unresected locally advanced HNSCC from 130 medical centres globally were randomly assigned (1:1) to pembrolizumab (200 mg) plus chemoradiotherapy or placebo plus chemoradiotherapy.